Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

Evercore ISI analysts upgraded CRISPR Therapeutics stock from an In Line to an Outperform rating and increased the price target significantly to $99 from the previous $60. The upgrade comes as ...

Mark Mahaney, Evercore ISI Head of Internet Research, joins 'Closing Bell Overtime' to talk Airbnb and Roku earnings.

Five-star-rated analyst Mark Mahaney at Evercore ISI has downgraded his rating from Buy to Hold on The Trade Desk (TTD) after ...

Wall Street investment bank Evercore ISI (EVR) is pounding the table on Nvidia (NVDA) stock ahead of the chipmaker’s upcoming ...

Rich Ross, head of technical analysis at Evercore ISI, said that a breakout to an all-time high in the S&P 500 ( SP500 ), ( ...

Confluent (NASDAQ:CFLT – Get Free Report) had its target price upped by Evercore ISI from $32.00 to $40.00 in a report ...

Carlyle is wrapping up a two-year fundraising campaign for its eighth secondaries flagship, CEO Harvey Schwartz said on the ...

Zillow Group (NASDAQ:ZG – Get Free Report) had its target price boosted by equities research analysts at Evercore ISI from $75.00 to $90.00 in a research report issued on Wednesday,Benzinga reports.

Walgreens Chief Executive Officer Tim Wentworth reiterated on an earnings call last month that the company plans to divest ...

VillageMD, the health care clinic chain backed by Walgreens Boots Alliance Inc., is working with Evercore Inc. for assistance ...